Abbott Laboratories Q2: Flat Revenue, Lower Margins and Higher Debt

Abbott Laboratories reported Q2 FY2026 revenue of $11.164B, compared with $11.140B in Q2 FY2025. That represents growth of approximately 0.2%, leaving the top line effectively unchanged. Revenue was therefore the only one of the five report-card metrics to exceed its required reference period, and even that result was a narrow year-over-year improvement rather than a meaningful acceleration.

The more consequential change was below the revenue line. Operating income was $1.345B, producing an operating margin of 12.0%. The comparable Q2 FY2025 operating margin was 18.4%, so the margin contracted by 6.4 percentage points. The supplied materials do not provide segment results, expense bridges or management explanations sufficient to identify whether the decline came from product mix, acquisition-related costs, operating expenses or another factor.

Gross profit was $4.397B, equivalent to a gross margin of 39.4%. A comparable prior-year gross margin was not disclosed in the supplied quarterly history, which reports zero rather than a usable figure. It is therefore not possible to determine whether gross margin improved or deteriorated year over year. The difference between the 39.4% gross margin and the 12.0% operating margin nevertheless indicates that costs below gross profit were significant during the quarter.

GAAP EPS declined to $0.61 from $1.01 in Q2 FY2025, a decrease of 39.6%. Cash generation moved in the same direction. Cash from operations was $1.315B and capital expenditure was $399M, resulting in free cash flow of $916M. That was 40.5% below the $1.540B generated in the comparable prior-year quarter.

The balance sheet changed more sharply than the revenue line. Cash was $6.803B and debt was $29.638B, implying net debt of approximately $22.8B. The supplied FY2025 figure was $4.4B, meaning net debt increased by roughly $18.4B. The materials do not provide enough transaction or financing detail to allocate that increase, but its size means the quarter cannot be assessed solely as a temporary margin fluctuation. Financial flexibility is now materially lower than it was at the end of FY2025.

The quarter weakens the near-term quality of the earnings profile without demonstrating a deterioration in revenue demand. Revenue was stable, but operating income, EPS and free cash flow all declined materially. That combination matters because it suggests the principal issue in the reported period was the conversion of sales into profit and cash rather than an outright contraction in the top line.

Before this quarter, FY2025 provided a comparatively constructive reference point. Revenue grew 5.7% from FY2024 to $44.33B, operating margin improved to 18.2%, free cash flow reached $7.39B and ROIC was 9.8%. Q2 FY2026 did not extend that margin progression. Its 12.0% operating margin was below every quarterly operating-margin figure shown from Q2 FY2023 through Q4 FY2025, making the decline material relative to both the year-ago quarter and the recent operating history.

Free cash flow remains an important stabilizer. Supplied TTM free cash flow is $7.4B, equivalent to a 4.1% yield on the current $180.7B market capitalization. That is meaningful cash generation, but the latest quarter contributed less than the prior-year period. If the Q2 decline reflects timing, cash conversion could normalize in subsequent quarters. If it reflects a sustained increase in the cost base, the trailing figure will overstate the company’s forward cash-earning capacity.

The increase in net debt also changes how much tolerance the thesis has for weaker margins. At FY2025, net debt of $4.4B was modest relative to annual free cash flow of $7.39B. At $22.8B, net debt is now approximately three times that FY2025 free-cash-flow figure. This is not a full leverage ratio because EBITDA was not supplied, but it demonstrates that debt reduction and cash retention have become more important uses of future cash flow.

No management guidance or earnings-release commentary was provided. Consequently, there is no company forecast against which to classify the margin, EPS or free-cash-flow outcomes as temporary, planned or unexpected. The thesis must remain evidence-led: a subsequent recovery in operating margin and free cash flow would support normalization, while another quarter near current levels would point to a more persistent reset.

There is no prior SageNoodle valuation for Abbott Laboratories, so this article establishes rather than revises fair value. The base case is $104 per share, approximately 0.6% above the current price of $103.421. Under the required verdict rule, that is Fairly Valued because the estimated upside is well below the 15% threshold for an Undervalued classification.

The valuation uses the supplied TTM EPS of $3.58 because forward guidance and consensus estimates were not provided. In the bear case, a 22.0 times multiple produces approximately $79 per share. This case assumes the Q2 margin contraction persists, free-cash-flow conversion remains below the prior-year level and higher net debt limits the multiple the market will assign.

The base case applies 29.0 times TTM EPS, producing $103.82, rounded to $104 per share. The multiple is an explicit assumption rather than a historical average supplied in the materials. It is close to the current 28.9 times P/E and reflects a business that generated $7.4B of TTM free cash flow but has not yet demonstrated that Q2’s margin pressure will reverse.

The bull case applies 34.0 times TTM EPS, producing approximately $122 per share. Reaching that value would require operating margin to move back toward the FY2025 level, free cash flow to recover from the Q2 decline and net debt to begin falling. The quarter does not yet supply evidence for those conditions, which is why the current price already sits near the base-case value rather than offering a wide margin of safety.

The most direct challenge to the cautious interpretation would be a rapid margin recovery. If Q2 included temporary expenses or unusual timing that does not recur, the 12.0% operating margin may understate ongoing profitability. A return toward FY2025’s 18.2% operating margin, without a corresponding revenue decline, would improve earnings power and could justify the bull-case multiple.

The opposite risk is that the margin contraction proves structural. Revenue was almost unchanged year over year, so sustained pressure from the cost base could reduce EPS and free cash flow even if demand remains stable. In that case, valuing the shares on the supplied TTM EPS of $3.58 would be too generous because the trailing period would not represent forward profitability.

Balance-sheet execution is the second major test. Net debt rose from $4.4B at FY2025 to $22.8B in the latest quarter. If future free cash flow reduces that balance, the change may be manageable within a multi-year thesis. If debt remains elevated while margins and cash conversion stay weak, financial risk would be higher than reflected in the base case.

Finally, the absence of supplied guidance, segment disclosures and a press release limits the conclusions that can be drawn from one quarter. The next filing needs to show whether the weakness was concentrated or broad, whether free-cash-flow conversion is normalizing and whether net debt is declining. Until those points are visible in reported data, $104 is a reasonable central value rather than a high-conviction indication of upside.